ReviewJournal of controlled release : official journal of the Controlled Release Society2014
Injectable controlled release depots for large molecules.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy.Advanced drug delivery reviews · 2020Pooled it
- Predicting drug release from polymeric long-acting injectables using a machine learning approach to decode formulation-performance relationships.Drug delivery and translational research · 2026Article
- Engineering molecularly imprinted polymers for receptor-specific cancer therapeutics.Nanoscale · 2026Review
- Deferoxamine Improves Radiation-Induced Peripheral Neuropathy.Journal of cellular and molecular medicine · 2026Article
- Intracellular GRP78-Directed Delivery of Rapamycin by Biomolecular Condensates of Hydra-Elastin-like Polypeptides.Biomacromolecules · 2026Article
- PLGA-Based In Situ-Forming Implants, a Quality by Design Perspective.Pharmaceutics · 2026Review
- PLGA-Based Co-Delivery Nanoformulations: Overview, Strategies, and Recent Advances.Pharmaceutics · 2025Review
- Sustained-Release Intra-Articular Drug Delivery: PLGA Systems in Clinical Context and Evolving Strategies.Pharmaceutics · 2025Review
- The impact of product quality attributes on in vivo performance of bupivacaine multivesicular liposomes.Drug delivery and translational research · 2025Article
- Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications.Chemical reviews · 2025Review
- Local controlled release of stabilized monoclonal antibodies.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care.Pharmaceutics · 2025Review
- New Direction in Antimicrobial Delivery System: Preparation and Applications of Hydrogel Microspheres.Pharmaceutics · 2025Review
- Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies.Drug delivery and translational research · 2025Review
- Engineering the Ratios of Nanoparticles Dispersed in Triphasic Nanocomposites for Biomedical Applications.ACS applied materials & interfaces · 2025Article
- Injectable Hydrogels for Programmable Nanoparticle Release.Advanced functional materials · 2025Article
- Effect of PLGA raw materials on in vitro and in vivo performance of drug-loaded microspheres.Drug delivery and translational research · 2025Article
- Azithromycin-loaded PLGA microspheres coated with silk fibroin ameliorate inflammation and promote periodontal tissue regeneration.Regenerative biomaterials · 2025Article
- Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective.Molecular pharmaceutics · 2024Review
- Advancements in wound healing: integrating biomolecules, drug delivery carriers, and targeted therapeutics for enhanced tissue repair.Archives of microbiology · 2024Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Biodegradable, injectable depot formulations for long-term controlled drug release have improved therapy for a number of drug molecules and led to over a dozen highly successful pharmaceutical products. Until now, success has been limited to several small molecules and peptides, although remarkable improvements have been accomplished in some of these cases. For example, twice-a-year depot injections with leuprolide are available compared to the once-a-day injection of the solution dosage form. Injectable depots are typically prepared by encapsulation of the drug in poly(lactic-co-glycolic acid) (PLGA), a polymer that is used in children every day as a resorbable suture material, and therefore, highly biocompatible. PLGAs remain today as one of the few "real world" biodegradable synthetic biomaterials used in US FDA-approved parenteral long-acting-release (LAR) products. Despite their success, there remain critical barriers to the more widespread use of PLGA LARproducts, particularly for delivery of more peptides and other large molecular drugs, namely proteins. In this review, we describe key concepts in the development of injectable PLGA controlled-release depots for peptides and proteins, and then use this information to identify key issues impeding greater widespread use of PLGA depots for this class of drugs. Finally, we examine important approaches, particularly those developed in our research laboratory, toward overcoming these barriers to advance commercial LAR development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.